|
MechanismKRAS G12V inhibitors [+2] |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1IIT Phase I Clinical Study of YK0901 Injection for the Treatment of Advanced Solid Tumors With HLA-A * 11:01 Positive and KRAS G12V Mutation
This study is a single center, open, single arm, dose increasing early clinical study. The purpose of this study is to evaluate the safety and efficacy of YK0901 immunotherapy in the treatment of patients with advanced solid tumor whose tumor antigen KRAS G12V expression is positive (HLA-A * 11:01).
100 Clinical Results associated with Yingkai Saiwei (Beijing) Biotechnology Co., Ltd
0 Patents (Medical) associated with Yingkai Saiwei (Beijing) Biotechnology Co., Ltd
100 Deals associated with Yingkai Saiwei (Beijing) Biotechnology Co., Ltd
100 Translational Medicine associated with Yingkai Saiwei (Beijing) Biotechnology Co., Ltd